uniQure N.V. (QURE)
NASDAQ: QURE · Real-Time Price · USD
17.95
+0.22 (1.24%)
At close: Sep 5, 2025, 4:00 PM
18.00
+0.05 (0.28%)
After-hours: Sep 5, 2025, 6:54 PM EDT
uniQure Revenue
uniQure had revenue of $5.26M in the quarter ending June 30, 2025, a decrease of -52.71%. This brings the company's revenue in the last twelve months to $14.34M, down -48.25% year-over-year. In the year 2024, uniQure had annual revenue of $27.12M with 71.17% growth.
Revenue (ttm)
$14.34M
Revenue Growth
-48.25%
P/S Ratio
64.69
Revenue / Employee
$68,598
Employees
209
Market Cap
1.22B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 27.12M | 11.28M | 71.17% |
Dec 31, 2023 | 15.84M | -90.64M | -85.12% |
Dec 31, 2022 | 106.48M | -417.52M | -79.68% |
Dec 31, 2021 | 524.00M | 486.49M | 1,296.82% |
Dec 31, 2020 | 37.51M | 30.23M | 415.23% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
QURE News
- 1 day ago - uniQure: Getting Nervous Ahead Of Critical Huntington's Gene Therapy Data - Seeking Alpha
- 1 day ago - uniQure Announces Initial AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease - GlobeNewsWire
- 5 weeks ago - What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday? - Benzinga
- 5 weeks ago - uniQure N.V. (QURE) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress - GlobeNewsWire
- 6 weeks ago - uniQure to Announce Second Quarter 2025 Financial Results - GlobeNewsWire
- 3 months ago - uniQure Announces Appointment of Kylie O'Keefe as Chief Customer and Strategy Officer - GlobeNewsWire
- 3 months ago - uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease - GlobeNewsWire